Dr Lal PathLabs Ltd on Thursday disclosed that it will acquire a 70% stake in SN Genelab Private Ltd for a cash consideration of up to ₹168 crore, plus a performance‑linked earn‑out capped at ₹31.5 crore. The transaction, approved by the board, will make SN Genelab a subsidiary, with completion slated for 30 Nov 2026.
SN Genelab, founded in 2013, posted a FY26 turnover of ₹57.96 crore, up from ₹53.36 crore in FY25 and ₹43.27 crore in FY24, signalling steady growth in the genomics‑diagnostics niche.
Dr Lal’s FY26 results show a 12.2% revenue rise to ₹702.7 crore and a 5.2% volume increase, yet net profit fell 15.2% YoY to ₹131.3 crore. The company’s stock closed at ₹1,958.80 on the BSE, up ₹36.20 or 1.88%.
Analysts note that the 13‑15% revenue guidance for FY27, coupled with an EBITDA margin target of 27‑28%, aligns with mid‑to‑high single‑digit growth seen in comparable diagnostics peers. The deal is expected to add advanced genomics capabilities, potentially offsetting the modest volume growth.
Looking ahead, Dr Lal’s CEO Shankha Banerjee warned that pricing will remain stable, but cost pressures will be monitored. Integration of SN Genelab’s services is slated to bolster the firm’s portfolio ahead of the FY27 earnings release on 31 Mar 2027.